B
lood is a critical, lifesaving resource in many clinical scenarios and ensuring the safety and adequacy of the blood supply is integral to public health and patient care. Therefore, monitoring and understanding the nature of the changes in blood collection and use are important to ensure the adequacy of the national blood supply. Blood collections and transfusions in the United States have declined since 2008. 1, 2 From 1997 to 2011, the National Blood Collection and Utilization Survey (NBCUS) was conducted biennially by AABB, with support from the Office of the Assistant Secretary for Health in the U.S. Department of Health and Human Services, with the primary aim of quantifying blood collection and utilization in the United States. [3] [4] [5] [6] The survey has been conducted by the Centers for Disease Control and Prevention (CDC) in collaboration with Office of the Assistant Secretary for Health 1,2 since 2013.
In addition to questions designed to elicit the quantity of blood and blood components collected, processed, tested, distributed, and transfused, the NBCUS contains several sections relevant to blood supply safety and adequacy. These include blood donor and donation characteristics, blood inventory and supply, blood product costs, platelet (PLT)-related testing, transfusion dosing, clinical use, hospital policies, and practices related to transfusion services and donor and recipient adverse reactions. The survey has been modified periodically to provide better characterization of blood collection and use and additional insight into healthcare delivery, clinical practices, and adoption of health-related technologies in the United States. The information generated from the survey has been used to guide public health policy, preparedness, and emergency response efforts to ensure blood supply sustainability. 7 Findings from the 2013 and 2015 NBCUS surveys related to collection, processing, distribution, and transfusion of blood products have been published previously and in this supplement. 1, 2 The remaining findings of these two surveys are presented here.
METHODS
Detailed methods of the 2013 and 2015 surveys have been published previously. 1, 2 Both surveys were administered electronically through a Web-based portal at the CDC. All sampled facilities were sent a link to the survey (specific to their institution) through e-mail. The survey instruments were designed to allow for reliable estimation of trends and variability in blood collection and utilization practices in comparison to previous years. The 2013 survey instrument was identical in design and content to the 2011 questionnaire and utilized analogous method in sample frame selection. For the 2015 instrument, the questionnaire was shortened to improve response rate and reduce respondent burden. For 2015, the sampling frame was identical to previous surveys; however, respondent follow-up, sampling, and analysis techniques were modified.
Questionnaire design
The 2013 survey instrument consisted of 16 questions related to blood donation and collection, 26 questions related to blood utilization, three questions related to bacterial testing of PLTs, and 15 questions related to patient blood management. The questionnaire also included sections on cord blood collections, human tissue, and cellular therapies, all of which had very low response rates and are not included in this report. The 2015 survey instrument consisted of 14 questions related to blood donation and collection and 28 questions related to blood utilization. A number of questions were included in a tabular format to enhance clarity and encourage completeness. New questions were added in 2015 pertaining to genotyping of red blood cell (RBC) antigens at blood centers, transfusion of genotyped RBC units at hospitals, the average pool size of whole blood-derived PLTs and cryoprecipitate, and the routine prophylactic dosing of PLTs. Some questions pertaining to mobile blood drives and intravenous immunoglobulin were eliminated due to poor response in the 2013 survey. Patient blood management-related questions were included in 2013 but were not included in the 2015 survey.
Sampling method
Construction of the sampling frames for both surveys followed similar method. Blood collection centers in the 50 states and the District of Columbia were identified from the Food and Drug Administration (FDA) Blood Establishment Registration database and from the America's Blood Centers membership list. 8 The FDA Blood Establishment
Registration databases for the 2013 and 2015 samples were retrieved in August of 2014 and 2015, respectively. Military facilities were excluded from both surveys and the remaining nonhospital (i.e., community) and hospitalbased blood collection centers were sent unique links requesting a response. Transfusing hospitals in the 50 states and the District of Columbia were identified from the American Hospital Association (AHA) annual survey database. The 2012 and 2013 AHA databases were used for the 2013 and 2015 NBCUS surveys, respectively. Hospitals performing fewer than 100 inpatient surgical procedures, military, Department of Justice, psychiatric, rehabilitation, long-term acute care, specialty treatment institutions, and facilities located in US territories were excluded from the sampling frame. For the 2013 survey, all facilities in the sampling frame were sent a survey, excluding 621 for which active contact information could not be determined which gave a total of 3549 facilities surveyed. The 2013 survey opened for participation in December 2014, and data collection concluded in March 2015. Nonrespondents to the 2013 survey were contacted by e-mail and phone before the March 2015 deadline to enhance response rates. In the 2013 survey, all hospitals performing more than 100 inpatient surgeries annually, as reported to the AHA, were sampled.
In the 2015 survey, 40% of hospitals performing 100 to 999 surgeries were randomly sampled with all other eligible hospitals sampled at 100%. This change reduced the number of facilities requiring follow-up and was consistent with survey method from the 2011 survey and prior years. Second, to enhance the response rate, a letter was sent by US mail 2 months before the survey launch to facility administrators of each blood center and hospital included in the sample to notify them of the upcoming survey. The 2015 survey opened for participation in March 2016, and data collection concluded in June 2016. Nonrespondents for the 2015 survey were contacted with a reminder by e-mail, telephone, and US mail to further boost responses. Follow-up for incomplete or inconsistent responses continued through August 2016 for the 2015 survey.
Disaggregation of responses by facilities
In 2013, hospital respondents were able to include aggregated data from multiple hospitals, which was later apportioned by surgical volume. 1 In 2015, hospital respondents were unable to submit aggregated responses for multiple facilities on a single survey as each hospital was assigned a unique survey link. 2 However, five hospital respondents included data for satellite facilities that were apportioned using the same technique used in 2013. Nonhospital blood collection center respondents entered information at the blood center level, which could include blood collection data from constituent facilities in multiple locations; no disaggregation was required, however, since all blood collection data were analyzed at the administrative blood center level.
Imputation
Missing data in both the 2013 and the 2015 surveys were imputed using identical multiple imputation method. All imputed variables were continuous and nonnormally distributed. A two-stage imputation procedure was performed for variables with distributions skewed toward zero. 9 Per established multiple imputation logic, imputation factors were considered for each variable to assure that the variables used for imputation had similar distributions to the variables requiring imputation. 10 Imputation was only applied to variables with no more than 20% missing data among the respondents. For questions where missing data exceeded 20% of respondents, an available case analysis was used. Questions that were not weighted to the national level were also not imputed. Imputation and weighting were used to generate national annual estimates for the total number of donations, volunteer or allogeneic donors, autologous and directed donors and recipients, plasma components distributed, recipient adverse reactions, donor adverse reactions, and crossmatch procedures. The percentage of missing data was too high for reliable imputation in the generation of national estimates for the number of pediatric transfusions and recipients, units transfused by location, and plasma components transfused; for national estimates, these variables were weighted without imputation, with weights based on the available cases to ensure a reliable national estimate. The remaining variables were not weighted and are presented as means, medians, or percentages of all responding facilities. Where appropriate, hypothesis testing was conducted using survey-based regression techniques to test for significant differences between years, with p-values less than 0.05 denoting significance. All analyses were conducted with statistical software (SAS, Version 9.3, SAS Institute).
Facility stratification
In 2013 and 2015, collection facilities were stratified into groups based on previous collection volume and hospitals were stratified based on annual inpatient surgical volume. Community-based, nonhospital blood collection centers were stratified into four categories based on the following annual RBC collection volume categories: less than 50,000, 50,000 to 199,999, 200,000 to 399,000, and 400,000 or more units. Annual RBC collection volume was not available for all hospital-based blood collection centers, and so inpatient surgical volume was used as a proxy for collection volume. Hospital-based blood centers were stratified into three categories based on annual inpatient surgical volume: less than 1000, 1000 to 7999, and 8000 or more inpatient surgeries. Transfusing hospitals were stratified into six categories based on annual surgical volume: 100 to 999, 1000 to 1399, 1400 to 2399, 2400 to 4999, 5000 to 7999, and 8000 or more inpatient surgeries.
Responses were weighted to adjust for nonresponse within strata. Sample weights were calculated for blood collection centers by dividing the total number of eligible participants by the number of actual respondents for each stratum, per the stratification scheme described. Blood collection centers with an expected collection volume of at least 400,000 units were assigned a weight of 1.0; all other collection centers and transfusing hospitals were weighted according to strata-specific inverse response rates. For transfusing hospitals, weighting was conducted in a similar manner with strata defined using surgical volume, as described. In 2015, hospitals with 100 to 999 surgeries per year that had been sampled at a rate of 40% were weighted for nonresponse and for sampling with the exception of nine facilities in this strata that also collect blood; nine such facilities were therefore sampled at 100% following the strategy for blood collection centers and were weighted for nonresponse only (eight of nine facilities responded). Confidence intervals (CIs) for national collection and transfusion estimates were calculated using the Taylor series method.
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To determine whether reported differences in utilization estimates generated from the 2013 and 2015 surveys were due to differences in sampling and response rates, a subset of transfusing hospitals was created with only respondents who had completed both the 2013 and the 2015 surveys. Not all hospitals from the 2013 survey could be matched, due to closures, mergers, openings, or differences in sampled facilities in the 100 to 999 surgeries per year strata. The matched subset was used to conduct sensitivity analysis of hospital policies and practices to enhance safety of recipients of blood or blood products and pediatric transfusions.
Variables analyzed for this report
National estimates for the collection and transfusion of allogeneic, autologous and directed whole blood, apheresis RBCs, whole blood-derived and apheresis PLTs, plasma and cryoprecipitate, rejected donations, outdates, and donor deferrals have been published for both surveys. 1, 2 For this report, we present the remaining information collected in 2013 and 2015 to supplement the results that have already been published.
Survey participation for 2013 and 2015 is summarized by facility type, by facility size as measured by the number of collections or surgical procedures per year, and by geographic region as defined by public health service (PHS) regions. Next, donor characteristics are explored with national estimates of the number of donors stratified by age and the number of first-time and repeat donors and donations for 2013 and 2015, as well as national estimates of autologous and repeat donors, donations, recipients, and transfusions for RBCs, PLTs, and plasma (where surveyed). Summary statistics are presented for cost estimates based on reports of amount paid per unit by hospitals for 2013 and 2015 for all facilities and stratified by annual surgical volume for seven component types as well as more detailed stratification of unit costs for RBCs, apheresis PLTs, and fresh-frozen plasma (FFP) by PHS region, hospital size as measured by number of beds and group purchasing status. Policies and practices in hospitals are summarized for 2013 and 2015, including hospital policy to transfuse only leukoreduced units; programs to treat patients who refuse transfusion on religious, cultural, or personal reasons; number of transfusion safety officers (TSOs) on staff; and retention of data on data collection errors.
National estimates of adverse reactions associated with donation or transfusions are presented for a range of transfusion-related adverse reactions and for severe donor adverse reactions associated with manual and automated collections. Patient blood management is summarized for 2013, including the percentage of facilities following various practices, standards and guidelines, and the percentage of facilities implementing various interventions pre-, intra-, and postoperatively. Issues related to the testing and use of PLTs are presented for 2013 and 2015, including the percentage of facilities using PLT additive solutions (PASs), the percentage of facilities performing pretransfusion bacterial testing, and the type of pretransfusion bacterial test used. Collection and transfusion of plasma stratified by product type is presented for 2013 and 2015.
Inventory, dosing, and supply issues are presented using summary statistics to describe the following: pediat- 
RESULTS

Survey participation
Since 2007, the overall response rate for the NBCUS had steadily declined until 2015 (Table 1) . Participation by community-based collection centers has remained steady with a response rate of at least 90% for five of the past six surveys; in 2013, the response rate for community-based collection centers was 64.8%. The largest difference in survey participation for community-based collection centers between 2013 and 2015 was among blood centers with fewer than 50,000 RBC collections annually (56.9% participation in 2013 vs. 92.5% participation in 2015). Among centers with 200,000 to 399,000 RBC collections annually, the number of facilities within this category reduced from seven to four, which drove the participation rate up from 42.9% in 2013 to 75.0% in 2015 (Table 2) .
Response rates among hospital-based collection centers increased from 41.2% in 2013 to 71.8% in 2015 ( Table 4 ). The mean number of autologous units transfused per recipient increased from 1.7 units in 2013 to 2.3 in 2015.
Donor characteristics
The number of directed units donated remained stable from 2013 to 2015. The number of recipients of directed RBC transfusions was unchanged. The number of RBC units transfused increased from 44,000 (95% CI, 25,000-64,000) in 2013 to 66,000 (95% CI, 35,000-96,000) in 2015 therefore resulting in an increase in the number of directed RBC units per recipient from 2.1 in 2013 to 2.6 in 2015. There were 9000 (95% CI, 5000-18,000) directed RBCs that were crossed over to the community supply in 2013. In 2013, 8000 (95% CI, 0-18,000) directed PLT units were collected and 2000 (95% CI, 1000-3000) were transfused compared with 6000 (95% CI, 1000-12,000) units collected and 5000 (95% CI, 3000-8000) transfused in 2013.
Cost
The price paid for blood products as reported by hospitals declined in 2015 for nearly all components in comparison to 2013. The median difference reported in price paid per unit between 2013 and 2015 decreased by $10 for leukoreduced RBCs, by $16 for apheresis PLTs, by $5 for plasma frozen within 8 hours of donation, and by $6 for plasma frozen between 8 and 24 hours of donation (PF24). Declines in the reported mean price paid per unit were significant for leukoreduced RBCs and apheresis PLTs. Nonleukoreduced RBC cost was not included on the 2015 survey, but the 2013 survey shows that the mean cost of nonleukoreduced RBCs was $10 less than leukoreduced RBCs. The median price reported per unit of cryoprecipitate increased by $2, with a larger significant increase in the mean price (Table 7) .
Leukoreduced RBCs
The median price paid as reported by hospitals for leu- (Table 7) . For both years, hospitals performing the fewest surgeries (100-999) reported paying the highest median prices for leukoreduced RBCs, and hospitals performing the greatest number of surgeries (>8000) reported the lowest median prices (Table 8 ). During 2015, hospitals performing 100 to 999 inpatient surgeries annually reported a median price of $215 per leukoreduced RBC unit, and hospitals performing more than 8000 inpatient surgeries reported a median price of $208. Similarly, in 2013, hospitals performing 100 to 999 inpatient surgeries reported a median price of $232 and those performing more than 8000 inpatient surgeries reported $215. When stratified by PHS region, the median cost reported by hospitals for leukoreduced RBCs was lower in 2015 than in 2013 for every region (Table 9 ). Transfusing hospitals in PHS Region 1 (CT, MA, ME, NH, RI, and VT) reported the highest median price paid per unit for leu- 
Apheresis PLTs
The median price reported by hospitals for apheresis PLTs overall was $524 (IQR, $495-$560) in 2015 and $540 (IQR, $510-$590) in 2013 (Table 7) . For both years, when stratified by annual inpatient surgical volume, hospitals performing the fewest inpatient surgeries (100-999) reported the highest median prices for apheresis PLTs, and hospitals performing the greatest number of inpatient surgeries (>8000) reported the lowest median prices (Table 8) . During 2015, hospitals performing 100 to 999 inpatient surgeries annually reported a median price of $540 per apheresis PLT unit, and hospitals performing more than 8000 inpatient surgeries reported a median price of $510. Similarly, in 2013, hospitals performing 100 to 999 inpatient surgeries reported a median price of $550 and those performing more than 8000 inpatient surgeries reported $524.
When stratified by PHS region, the median cost reported per hospital was lower in 2015 than 2013 for every region, except for Region 8 (CO, MT, ND, SD, UT, WY), although the number of hospitals contributing cost data was lowest for Region 8 in both years, and response within the region differed for each year (n 5 28 in 2013 and n 5 67 for 2015; Table 9 
Whole blood-derived PLTs
Whole blood-derived PLT transfusions accounted for 8.3% of all PLT transfusions, when counted as apheresis equivalent units with a median pool size of 5 in 2015. 2 The median price reported by hospitals for each unit of whole blood-derived PLTs was $95 (IQR, $68-$420) in 2015 based on 101 facilities ( Table 7) . Cost of whole blood-derived PLTs was not asked in 2013. When stratified by annual inpatient surgical volume, hospitals performing the fewest inpatient surgeries (100-999) reported the highest median prices for whole blood-derived PLTs ($159), and hospitals performing the greatest number of inpatient surgeries (>8000) reported the lowest median prices ($80; Table 8 ).
Larger hospitals were more likely to use whole bloodderived PLT units than smaller hospitals, with 23.3% of hospitals performing the more than 8000 inpatient surgeries reporting whole blood-derived PLT usage in 2015 and only 7.5% of hospitals performing the 100 to 999 inpatient surgeries reporting whole blood-derived PLT usage in 2015. (Table 7) . During 2015, hospitals performing 100 to 999 inpatient surgeries annually reported a median price of $60 per FFP unit, and hospitals performing more than 8000 inpatient surgeries reported a median price of $47. In 2013, hospitals performing 100 to 999 inpatient surgeries also reported a median price of $60 and those performing more than 8000 inpatient surgeries reported $56 (Table 8) .
When stratified by PHS region, the median cost reported per hospital was lower in 2015 than in 2013 for every region, except for Regions 1 and 10, which may be attributable to the small strata size in 2013 (Table 9) . 
Facility characteristics
For leukoreduced RBCs, apheresis PLTs, and FFP, the largest hospitals (500 beds) reported the lowest median price per unit in 2015 ($206 for leukoreduced RBCs, $517 for PLTs, and $50 for FFP) and the smallest hospitals (<200 beds) reported the highest price per unit in 2015 ($214 for leukoreduced RBCs, $530 for apheresis PLTs, and $58 for FFP). For all three components assessed, lower median prices per unit were reported by transfusing hospitals that were members of larger healthcare systems or networks and for transfusing hospitals that participated with an in-group purchasing agreement in 2015 (Table 10) .
Hospital policies and/or practices related to transfusion services 39 .0% responded that the TSO was a full-time employee, and 61.0% responded that the TSO was a part-time employee. The majority of TSOs (94.2% in 2013 and 94.9% in 2015) were employees of the hospitals rather than of the hospital blood center. Finally, the proportion of hospitals collecting information on sample collection errors decreased slightly from 85.3% to 83.8% in the overall sample, but increased by 1.5% in the matched sample (Table 11 ). The mean number of sample collection errors across responding facilities was 37.0 per facility in 2015.
In 2015, 2% of hospitals (31/1883) reported genotyping for RBC antigens in the hospital; at these hospitals, a mean of 17.4% (median, 2.5%) of all RBC units were genotyped. The proportion of blood centers reporting genotyping of donors was 19% (31/162); at these blood centers the mean proportion of donors genotyped was 6.4% (median, 3.0%).
Adverse reactions
Estimates of transfusion-associated adverse reactions were collected for 17 different categories in 2013 and 2015. Respondents were also asked separately for the total number of reactions that required any diagnostic or therapeutic intervention and the total number of reactions considered life-threatening. Table 12 † Diagnostic tests were defined as "any test to confirm a reaction occurred" and therapeutic intervention was defined as "intervention to treat a reaction (e.g., vasopressors, intubation, transfer to intensive care to prevent impairment, permanent damage, or death)." ‡ Zero events reported in the sample for 2013, so no national estimate of the number of occurrences could be made. § For example, vasopressors, blood pressure support, intubation, or transfer to the intensive care unit.
graft-versus-host disease (GVHD) was reported in 2015, with zero cases reported in 2013. The number of severe donor adverse reactions associated with manual whole blood collections and automated (apheresis) collections stratified by facility type are shown in Table 13 . There was a minor increase in donor adverse reactions for both manual whole blood (1:1006 in 2013 to 1:756 in 2015) and automated collections (1:904 in 2013 to 1:784 in 2015), although the error associated with these estimates is large, as represented by the CI for the combined estimates (14,577,000 reactions with a 95% CI of 11,462,000-17,692,000 in 2013 and 17,762,000 reaction with a 95% CI of 10,744,000-24,779,000 in 2015). The number of reactions among hospital-based blood collection centers in 2013 was very small (328 total in 2013 compared with 2431 in 2015), which may reflect the difficulty of estimating rare events with the low response rate of the 2013 survey. In 2015, relative parity between reaction rates was observed for manual (1:854) and automated (1:786) collections in blood centers and automated collections (1:752) in hospital-based collection blood centers with a higher reaction rate for manual collections (1:237) by hospital-based blood collection centers.
Patient blood management
The 2013 survey queried respondents on patient blood management and related transfusion safety efforts. This section was not included in the 2015 survey. Of the 899 responding facilities, 50.3% (452/899) reported having a patient blood management program (Table 14) Table 14 ). Of 615 reporting facilities, 70.2% (432/615) evaluated patients facing elective surgeries associated with high likelihood of blood loss for factors predictive of pre-and postoperative anemia; of those facilities, 284 answered a follow-up question with 69.4% (197/284) responding that they had a program to manage patient anemia before surgery. The ordering provider was required to obtain and document informed consent for transfusion in 94.1% (904/961) of facilities. Physicians were required to document the reason or clinical justification for transfusion in the patient's medical record at 81.9% (729/890) of facilities. Documentation of relevant pretransfusion laboratory results for nonemergent transfusions was reported as being required at 79.1% (714/903) of facilities. A computerized physician order entry (CPOE) was reported as being required at 85.1% (847/995) of facilities, and 56.1% (474/845) of the CPOEs included transfusion guidelines or an algorithm to assist with proper transfusion ordering.
Facilities were asked to report on the interventions implemented to reduce the likelihood of allogeneic transfusion (Fig. 2) , regardless of whether they had a patient blood management program. In the preoperative setting, interventions included a clinical assessment for anemia (reported by 41 
PLT related considerations
In 2013, blood collection facilities were asked to indicate whether Intersol (Fenwal) PAS was used to prepare apheresis PLTs. In 2015, the question was expanded to include all PAS, with no specific question eliciting Intersol use. Only four of 113 (3.5%) facilities reported using Intersol PAS in 2013 with a mean number of treated PLTs of 43 units per facility treated with Intersol in 2013 (based on three of four facilities reporting). A greater number of facilities reported using PAS in 2015 (6.8%; 11/162 facilities) with a mean of 3374 units using PAS per facility (Table 15) . * n/N gives the number of respondents who answered yes over the total number of respondents. Table 17 describes the testing methods reported by responding facilities for pretransfusion bacterial testing of PLTs in community-based collection centers for 2013 and for hospitals (including hospital-based collection centers) in 2013 and 2015. As previously described in Table 16 , the number of hospitals performing pretransfusion bacterial testing of PLTs for 2013 and 2015 represents a small percentage of all hospitals (3.1 and 2.0%, respectively) so that the aggregated test results in Table 16 are based on a small sample. Not all facilities that reported performing pretransfusion bacterial testing of PLTs responded to the question on test type. In community blood banks, the most common testing method for apheresis PLTs was culture-based testing (35/42 facilities in 2013). Culturebased tests were also the most common for whole bloodderived PLTs (10/42 facilities for pooled units and two facilities for single units). Rapid immunoassay was rarely used by community blood centers (one facility each for single and pooled units out of 42 facilities that performed bacterial testing of PLTs). Positive results occurred in 76 of 308,941 (0.025%) tests.
Hospitals and hospital-based blood centers that performed pretransfusion bacterial testing of PLTs used rapid tests more often than culture-based testing for whole blood-derived units, but culture-based tests were the most common test type for apheresis PLTs, aside from In 2015, distributions were surveyed for whole bloodderived and apheresis plasma. Most plasma distributed came from whole blood collections, but the proportion of apheresis collections that were processed into FFP units (26.3%) was higher than the proportion of collections that were processed into PF24 units (6.8%). The number of units transfused as pediatric-size FFP (29,000, 95% CI, 20,000-38,000 in 2015; and 28,000, 95% CI, 18,000-39,000 in 2013), jumbo-size FFP (37,000, 95% CI, 15,000-59,000 in 2015; and 28,000, 95% CI, 11,000-44,000 in 2013), liquid plasma (12,000, 95% CI, 5-19,000 in 2015; and 12,000, 95% CI, 0-26,000 in 2013), and group AB plasma (223,000, 95% CI, 184,000-262,000 in 2015; and 259,000, 95% CI, 210,000-308,000 in 2013) was similar for 2013 to 2015. Additionally, in 2013, a total of 6,825,000 (95% CI, 6,045,000-7,604,000) plasma units were distributed for further manufacture by blood centers. This question was not asked in 2015.
Inventory-, dosing-, and supply-related considerations
In 2013 and 2015, hospitals were asked to report dosing criteria for plasma transfusions, and in 2015 hospitals were additionally asked to report dosing criteria for prophylactic and therapeutic PLT transfusions. Table 19 displays the number of facilities that used each listed dosing criteria for plasma or PLT dosing. The majority of hospitals responding to this question reported using dosage that varied based on level of thrombocytopenia or bleeding (63.8% of facilities in 2013, 67.2% of facilities in 2015) for plasma dosing. Of the remaining facilities, 8.5% of facilities in 2013 and 9.0% of facilities in 2015 reported using a standard number of units per dose for plasma, 6.3% of facilities in 2013 and 5.8% of facilities in 2015 reported using weight-based dosing for plasma, and 21.4% of facilities in 2013 and 18.0% of facilities in 2015 reported using a method inconsistent with the choices given. A similar pattern was observed for PLTs (not included on the 2013 survey) with 67.0% of prophylactic PLT transfusions and 71.5% of therapeutic PLT transfusions using dosage that varied based on level of thrombocytopenia or bleeding, 12.0% of prophylactic PLT transfusions and 10.8% of therapeutic PLT transfusions using a standard number of units per dose, 1.6% of prophylactic PLT transfusions and 1.3% of therapeutic PLT transfusions using weight-based dosing, and 19.4% of prophylactic PLT transfusions and 16.4% of therapeutic PLT transfusions using a method inconsistent with the choices given.
Hospitals were asked to report their average pretransfusion laboratory test results for RBCs, PLTs, plasma, and cryoprecipitate. This question was not included on the 2015 survey. The mean and standard deviation (SD) from those facilities that reported laboratory results are shown in Table 20 . Of the 1101 facilities that responded to the 2013 survey, pretransfusion laboratory results were provided by 433 facilities for RBCs, 363 for PLT, between 137 and 242 for plasma, and 139 for cryoprecipitate. In patients undergoing RBC transfusion, the estimated mean pretransfusion hemoglobin (Hb) level was 10.2 g/dL (SD, 15.0 g/dL; Table 20 ). In patients undergoing PLT transfusion, the estimated mean pretransfusion PLT count was 9590.4 3 10 6 /L (SD, 17,698.2 3 10 6 /L). In patients undergoing plasma transfusion, the estimated mean pretransfusion prothrombin time was 15.0 seconds (SD, 24.9 sec) and partial thromboplastin time was 59.7 seconds (SD, 36.6 sec). In patients undergoing cryoprecipitate transfusion, the estimated mean pretransfusion fibrinogen level was 108.4 mg/dL (SD, 64.9 mg/dL).
In 2013, a total of 995 facilities reported their standard RBC order for nonbleeding patients. The majority of facilities (51%) reported a standard order of 2 units of RBCs, while 33% of facilities reported a standard order of 1 unit. In 2013, the mean age for components transfused was In 2013, a total of 934 of 1101 facilities reported average weekday inventories of group O RBC units that varied by hospital size, from 15.9 units in hospitals performing 100 to 999 inpatient surgeries per year to 137.6 units in hospitals performing more than 8000 inpatient surgeries per year (Table 22 ). The number of group O1 RBC units at which supply was considered critically low ranged from a mean of 7.1 units in hospitals performing 100 to 999 inpatient surgeries per year to a mean of 71.0 units in hospitals performing more than 8000 inpatient surgeries per year. In 2015, the group O RBC supply maintained by hospitals on an average weekday was 13.3 RBC units in hospitals performing 100 to 999 inpatient surgeries per year and 135.3 units in hospitals performing more than 8000 inpatient surgeries per year, as reported by 1883 hospitals. The number of group O1 RBC units at which supply was considered critically low decreased from 2013, from 5.7 units in hospitals performing 100 to 999 inpatient surgeries per year to 61.2 units in hospitals performing more than 8000 inpatient surgeries per year.
The number of crossmatch procedures performed on whole blood and RBCs in 2013 and 2015 is shown in Table 23 . There was an overall decline in the number of crossmatch procedures by any method from 19,042,000 in 2013 to 16,625,000 in 2015. This represents a 12.7% decline form 2013, which is a larger decrease than the 
Pediatric transfusions by US blood centers and hospitals
The number of adult-equivalent units transfused to pediatric patients is shown in Table 24 along with the number of pediatric recipients. The number of adult-equivalent units (all components) used for pediatric patients was lower in 2015 than in 2013. The number of whole blood and RBC units, apheresis PLT units, and plasma units transfused decreased. Similarly the total number of pediatric transfusion recipients decreased in 2015 in comparison with 2013.
Transfusion location
The number of RBCs and PLTs transfused by in-hospital location type in 2013 is shown in Table 25 along with the number of respondents. Approximately half of all responding facilities answered this question, with a slightly higher response rate among smaller facilities than larger facilities. In 2013, the largest number of RBC units were used in general medicine (2,872,000; 95% CI, 2,534,000-3,210,000), followed by hematology-oncology (1,842,000; 95% CI, 1,457,000-2,226,000), intensive care units (1,638,000; 95% CI, 1,417,000-1,859,000), general surgery (1,238,000; 95% CI, 983,000-1,494,000), and emergency departments (1,024,000; 95% CI, 893,000-1,155,000). The rest of the locations used fewer than one million RBC units: cardiac surgery (752,000; 95% CI, 600,000-905,000), orthopedic surgery (597,000; 95% CI, 416,000-777,000), nephrology (285,000; 95% CI, 233,000-336,000), obstetricsgynecology (230,000; 95% CI, 191,000-268,000), pediatricsneonatology (187,000; 95% CI, 126,000-247,000), and transplantation services (129,000; 95% CI, 53,000-205,000). The largest number of PLT units were used in hematology-oncology (645,000; 95% CI, 408,000-882,000) followed by general medicine (269,000; 95% CI, 213,000-326,000), critical care units (261,000; 95% CI, 201,000-322,000), cardiac surgery (170,000; 95% CI, 135,000-205,000), and general surgery (139,000; 95% CI, 111,000-168,000). The questionnaire modification for the 2015 survey included amalgamating surgical subspecialties into a single category, all surgery (including transplant). General medicine and hematology-oncology were combined into inpatient medicine. As with the 2013 survey, approximately half of all responding facilities answered this question, with a slightly higher response rate among smaller facilities than larger facilities. The pediatrics-neonatology location was separated into pediatrics and neonates (Table 26 ). In 2015, the largest number of RBCs were used in inpatient medicine, including hematology-oncology (4,293,000; 95% CI, 3,966,000-4,620,000), followed by critical care (1,817,000; 95% CI, 1,689,000-1,946,000), outpatient and nonacute inpatient settings (1,631,000; 95% CI, 1,477,000-1,786,000), all surgery including transplant (1,431,000; 95% CI, 1,284,000-1,578,000), emergency departments (1,007,000; 95% CI, 900,000-1,114,000), obstetrics-gynecology (194,000; 95% CI, 173,000-215,000), pediatrics (149,000; 95% CI, 89,000-208,000), and neonates (103,000; 95% CI, 79,000-128,000). The largest number of PLTs were also used in inpatient medicine, including hematology-oncology (866,000; 95% CI, 626,000-1,105,000), followed by critical care (400,000; 95% CI, 349,000-451,000), outpatient and nonacute inpatient settings (302,000; 95% CI, 240,000-365,000), and all surgery (including transplant; 300,000, 95% CI, 245,000-356,000). To compare transfusions by location for 2013 and 2015, locations were combined so that they could be matched (Table 27 ). The largest change in RBC use between 2013 and 2015 occurred in the all surgery category with a significant decrease of 41.5%. Increases were observed in RBC transfusion in pediatrics-neonatology (24.4%) and critical care (10.9%) but these differences were not significant. There was a significant increase in PLTs used in critical care settings. However, there were no significant changes in PLT use in other settings.
DISCUSSION
The findings presented here from the NBCUS for 2013 and 2015 provide further insight into the declining utilization of blood in the United States. The number of units transfused in surgical settings declined significantly between 2013 and 2015, which supports evidence that improvements in surgical techniques and adoption of patient blood management programs have resulted in decreased routine use of blood. [16] [17] [18] The overall decline in blood use may be attributable to decreasing use for surgical procedures. While questions related to patient blood management were not included in the 2015 survey, data from respondents in 2013 suggest that a large proportion of hospitals in the United States had adopted these programs, which include transfusion training, implementation of transfusion guidelines, anemia management, and evaluation for likelihood of blood loss during surgery. Despite progress toward reducing the need for transfusions for certain clinical indications, blood use in emergency and critical care settings did not decrease between 2013 and 2015. Blood remains a critical, lifesaving intervention for patients with urgent or complex clinical needs even though there has been an overall reduction in use.
Implications for maintaining an adequate blood supply
Findings from the NBCUS suggest an evolution in donor recruitment strategies by blood centers to address supply and adequacy. In 2015, blood centers reported a decline in first-time donors and an increase in repeat donors in comparison to 2013. Repeat donors are critical to maintaining overall volume of the blood supply and have lower incidence of infectious diseases than first-time donors. 19, 20 Repeat donations are likely to be a factor in the lower number of deferrals in 2015 when compared to 2011. Previously, due to concerns for an aging blood donor population, collection centers began to target younger age groups for donation. 21 Recruitment of young first-time donors, who are then encouraged to donate again within 1 year can secure long-term donation commitment. 22 The 2015 NBCUS findings reflect these efforts, suggesting continued shifts in blood donor age distributions with increases in the proportion of younger (i.e., <18) and older (i.e., 65) donors, with a corresponding decrease in the proportion of donors between 18 and 65 years of age. The increasing proportions of donors in the youngest and oldest age categories, particularly younger donors, has several implications for the blood supply. Young donors are more susceptible to adverse events such as injury related to falls from vasovagal syncopal reactions and phlebotomy-related complications. 23, 24 Additionally, younger donors are more susceptible to development of iron deficiency, which has prompted consideration for strategies to mitigate short-term and long-term consequences of repeat donation in this age group. [25] [26] [27] A careful approach to recruiting, maintaining, and assuring the safety of young donors is underscored by literature demonstrating that donors are less likely to return to donate if they experience an initial adverse reaction, which could discourage commitment to long-term repeated donation. 28 Reliance on older donors, aged over 65 years, may also result in future supply challenges. Older donors may experience medical conditions or receive prescription medications that result in deferral. Recently, the FDA changed the qualification standards for the acceptable minimum Hb and hematocrit levels for allogeneic male donors from 12.5 g/dL (38%) to 13.0 g/dL (39%). 29 This may decrease the number of eligible male donors and result in higher numbers of deferrals for low Hb. As a result of these concerns, blood centers may consider different approaches to donor recruitment and retention by targeting donors in early adulthood. Previous studies have projected that changes in the donor age demographic, coupled with an aging patient population that requires more blood, could lead to an inadequate supply unless offset by an increase in young and middleage donors. 21 
Costs
Declines in the demand for blood products may have contributed to decreases in the median cost paid per unit by transfusing hospitals. When comparing 2015 median prices per unit to 2013 prices paid by hospitals, declines were noted across all primary blood component types, including RBCs, PLTs, and plasma. Further, the price paid per unit varied inversely for all product types when stratified by surgical volume and bed size, with higher-volume hospitals paying the lowest price per unit and the lowest volume hospitals paying the highest prices. These findings are further consistent with published data showing that hospitals affiliated with major academic medical centers pay lower prices for blood products. 30 Reported prices were lower for hospitals which were members of group purchasing agreements or hospitals part of larger healthcare systems. The 2015 findings also demonstrate cost variations by PHS region, which is consistent with previous findings showing significant variation in prices paid for blood products by census region. 30 These declines in prices paid by hospitals for blood products may affect the ability of blood centers to maintain donations while absorbing and incorporating new safety interventions such as pathogen reduction technology. 31 
Adverse events
The risks associated with transfusion in the United States are low due to improvements in donor screening, automated data systems, and standardization of clinical transfusion practices. 32 However, the 2015 survey findings suggest an increase in life-threatening reactions which required major medical interventions. It is not clear which specific reaction types drove this increase in severe reactions, but the increase coincided with the recommended use of severity and imputability definitions for NBCUS, which are based on the National Healthcare Safety Network (NHSN) Hemovigilance Module. 33 The incorporation of NHSN case definitions for NBCUS in 2013 and 2015 could have led to more complete reporting of severe reactions among survey respondents. [34] [35] [36] Enhanced recognition of these reactions is important to prevent transfusion-related morbidity and mortality. The increased recipient adverse reaction rate points to the need for increased participation in national hemovigilance, which can enhance transfusion safety by allowing for ongoing monitoring of incidence and prevalence of reactions, identifying areas for intervention, and assessing the impact of safety measures. The NHSN Hemovigilance Module was developed to implement national surveillance of transfusion-associated adverse events. However, participation in the module is voluntary, with the exception of facilities in Massachusetts, and not yet nationally representative. Therefore, the NBCUS provides additional insight into the burden of recipient transfusion reactions nationally.
Respiratory reactions including TRALI, TACO, and transfusion-associated dyspnea have been the subject of recent efforts to reduce severe recipient reactions and to better define and harmonize case definitions. 37, 38 The occurrence of these reactions as reported to NBCUS by hospitals is consistent with results from analyses of the NHSN Hemovigilance Module data. 39 In both data systems, the rate of TRALI has remained stable or slightly declined which is likely a result of risk mitigation strategies, while rates of TACO and transfusion-associated dyspnea are increasing. 40 The apparent increase in these two respiratory reactions may reflect improved recognition, but should be the subject of further study. Enhanced recognition of respiratory reactions is vital as TRALI and TACO are the leading causes of transfusion reactionrelated deaths in the United States. 32 In addition to the respiratory reactions, rates of transfusion-transmitted infections as reported to NBCUS are consistent with the NHSN Hemovigilance Module. The increase in transfusion-transmitted bacterial and parasitic infections observed in both systems points to the need for further safety interventions. Donor adverse reactions can be mild to severe, can have short-or long-term implications for the donor (e.g., nerve damage), and can have a negative effect on blood donor return rate. 41 Therefore, NBCUS currently offers the only national estimates of donor adverse reactions. The present surveys demonstrate a slight increase in donor reaction rates from 2013 to 2015. Donor adverse reaction rates were similar for automated and manual collections in blood centers, consistent with previous observations, but higher for manual collections in hospital-based blood centers. 43 Previously, American Red Cross data have suggested high levels of variability in donor adverse reactions related to geographic location and donor demographics. 43 Although the present survey does not elicit specific reaction data, some explanations for higher reaction rates may be related to a higher proportion of donations from younger donors.
Adoption of practices and technologies
The 2013 and 2015 surveys contain valuable information regarding the adoption of practices and technologies to enhance blood safety including molecular genotyping of blood donors and units within hospitals and pretransfusion bacterial testing of PLTs. While blood bank laboratories routinely type donors and patients for ABO and D, serologic typing for other antigens can be labor-intensive and may delay the identification of compatible blood products for patients with multiple antibodies. 48 To obviate the need for serologic typing, high-throughput molecular assays have been developed, which can rapidly identify compatible units containing the appropriate profile of other antigens. 49 The present findings suggest that one in five blood collection centers genotyped donors in 2015, but those centers genotyped less than 10% of all donors; very few hospitals (2%) reported genotyping units, and among those that did, fewer than 1 in 5 units were subjected to genotyping on average. As this technology has become only recently available for testing blood donors, the adoption of molecular genotyping will likely grow in the future.
The results indicate that many hospital-based blood centers performed nonculture testing for bacterial detection of PLTs. Recently, the FDA released guidance regarding bacterial risk control strategies to enhance safety and availability of PLTs. 50 These recommendations include culture-based primary testing of PLT products or subjecting apheresis PLTs to pathogen reduction technology. 50 Future surveys will continue to monitor implementation of safety measures to reduce bacterial contamination of PLTs, such as primary culture-based testing and pathogen reduction technology.
LIMITATIONS
These findings are subject to several limitations. The response rate for 2013 was lower than that of previous surveys and the response rate for 2015 was substantially higher than in previous years. As a result of this disparity, the uncertainty (as reflected by CIs) in 2013 was higher than in 2015 and the chance of bias due to nonresponse is also higher for 2013. CIs reflect errors due to sampling and imputation but cannot include data input, transmission, or other errors and cannot be corrected for biases. Chung and colleagues 1 estimated that as many as onethird of nonrespondents may not have received the 2013 survey and the impact of the nonresponse is not clear. Additionally, respondents were allowed to aggregate responses over several facilities in 2013, so that these responses had to be approximately apportioned for analysis, a practice that introduces more uncertainty for 2013 estimates. These problems were resolved for the 2015 survey. For both surveys, weighting and multiple imputation were used to produce national estimates. These procedures are reliant on homogeneous strata, which were defined using annual inpatient surgical volume for hospitals or number of RBC collections for blood centers. Annual inpatient surgical volume information was based on AHA estimates for 2012 for the 2013 survey and based on 2013 for the 2015 survey, which were the most recent available at the time of survey development. This may have led to incorrect strata categorization. The impact on the estimates presented here are likely to be minimal. In addition, sampling of hospitals was designed using inpatient surgical volume consistent with previous surveys. However, as demonstrated in 2015, blood use for surgical procedures is declining. Future surveys should consider alternative sampling methodologies, based on different proxies for blood use.
CONCLUSIONS
While blood collection and use have declined in the United States, blood remains a critical resource for patients with urgent or complex clinical needs. Continued challenges in maintaining an adequate blood supply include declining costs paid per blood products and recruiting and retaining blood donors while considering donor safety. While the NBCUS provides additional information regarding transfusion-related reactions, findings from the 2013 and 2015 surveys support the participation in national hemovigilance. Future surveys will continue to monitor the adoption of new technologies related to blood collection and transfusion, including molecular genotyping and pathogen reduction technology.
